Literature DB >> 23413907

Vaccine strategies for glioblastoma: progress and future directions.

Christopher Jackson1, Jacob Ruzevick, Henry Brem, Michael Lim.   

Abstract

Recent advances in glioblastoma therapy have led to optimism that more effective therapies will improve outcomes. Immunotherapy is a promising approach that has demonstrated the potential to eradicate cancer cells with cellular-level accuracy while minimizing damage to surrounding healthy tissue. Several vaccination strategies have been evaluated for activity against glioblastoma in clinical trials. These include peptide vaccines, polyvalent dendritic cell vaccines, heat shock protein vaccines and adoptive immunotherapy. In this review, we highlight clinical trials representative of each of these approaches and discuss strategies for integrating these therapies into routine patient care.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23413907      PMCID: PMC4086484          DOI: 10.2217/imt.12.155

Source DB:  PubMed          Journal:  Immunotherapy        ISSN: 1750-743X            Impact factor:   4.196


  120 in total

Review 1.  Dendritic cells: immune regulators in health and disease.

Authors:  Mary F Lipscomb; Barbara J Masten
Journal:  Physiol Rev       Date:  2002-01       Impact factor: 37.312

2.  Controlled local delivery of interleukin-2 by biodegradable polymers protects animals from experimental brain tumors and liver tumors.

Authors:  J Hanes; A Sills; Z Zhao; K W Suh; B Tyler; F DiMeco; D J Brat; M A Choti; K W Leong; D M Pardoll; H Brem
Journal:  Pharm Res       Date:  2001-07       Impact factor: 4.200

3.  Vaccination of metastatic melanoma patients with autologous tumor-derived heat shock protein gp96-peptide complexes: clinical and immunologic findings.

Authors:  Filiberto Belli; Alessandro Testori; Licia Rivoltini; Michele Maio; Giovanna Andreola; Mario Roberto Sertoli; Gianfrancesco Gallino; Adriano Piris; Alessandro Cattelan; Ivano Lazzari; Matteo Carrabba; Giorgio Scita; Cristina Santantonio; Lorenzo Pilla; Gabrina Tragni; Claudia Lombardo; Flavio Arienti; Alfonso Marchianò; Paola Queirolo; Francesco Bertolini; Agata Cova; Elda Lamaj; Lucio Ascani; Roberto Camerini; Marco Corsi; Natale Cascinelli; Jonathan J Lewis; Pramod Srivastava; Giorgio Parmiani
Journal:  J Clin Oncol       Date:  2002-10-15       Impact factor: 44.544

4.  Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells.

Authors:  T Kikuchi; Y Akasaki; M Irie; S Homma; T Abe; T Ohno
Journal:  Cancer Immunol Immunother       Date:  2001-09       Impact factor: 6.968

5.  Selective depletion of inducible HSP70 enhances immunogenicity of rat colon cancer cells.

Authors:  S Gurbuxani; J M Bruey; A Fromentin; N Larmonier; A Parcellier; M Jäättelä; F Martin; E Solary; C Garrido
Journal:  Oncogene       Date:  2001-11-08       Impact factor: 9.867

6.  Cisplatin, dacarbazine with or without subcutaneous interleukin-2, and interferon alpha-2b in advanced melanoma outpatients: results from an Italian multicenter phase III randomized clinical trial.

Authors:  Ruggero Ridolfi; Vanna Chiarion-Sileni; Michele Guida; Antonella Romanini; Roberto Labianca; Andrea Freschi; Giovanni Lo Re; Rolando Nortilli; Sonia Brugnara; Patrizia Vitali; Oriana Nanni
Journal:  J Clin Oncol       Date:  2002-03-15       Impact factor: 44.544

7.  Novel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4.

Authors:  Alexzander Asea; Michael Rehli; Edith Kabingu; Jason A Boch; Olivia Bare; Philip E Auron; Mary Ann Stevenson; Stuart K Calderwood
Journal:  J Biol Chem       Date:  2002-02-08       Impact factor: 5.157

8.  Involvement of LOX-1 in dendritic cell-mediated antigen cross-presentation.

Authors:  Yves Delneste; Giovanni Magistrelli; Jean Gauchat; Jean Haeuw; Jean Aubry; Kayo Nakamura; Naoko Kawakami-Honda; Liliane Goetsch; Tatsuya Sawamura; Jean Bonnefoy; Pascale Jeannin
Journal:  Immunity       Date:  2002-09       Impact factor: 31.745

9.  Local immunotherapy with interleukin-2 delivered from biodegradable polymer microspheres combined with interstitial chemotherapy: a novel treatment for experimental malignant glioma.

Authors:  Laurence D Rhines; Prakash Sampath; Francesco DiMeco; H Christopher Lawson; Betty M Tyler; Justin Hanes; Alessandro Olivi; Henry Brem
Journal:  Neurosurgery       Date:  2003-04       Impact factor: 4.654

10.  Combination chemotherapy with or without s.c. IL-2 and IFN-alpha: results of a prospectively randomized trial of the Cooperative Advanced Malignant Melanoma Chemoimmunotherapy Group (ACIMM).

Authors:  J Atzpodien; K Neuber; D Kamanabrou; M Fluck; E B Bröcker; C Neumann; T M Rünger; G Schuler; P von den Driesch; I Müller; E Paul; T Patzelt; M Reitz
Journal:  Br J Cancer       Date:  2002-01-21       Impact factor: 7.640

View more
  18 in total

1.  Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM.

Authors:  Dimitrios Mathios; Jennifer E Kim; Antonella Mangraviti; Jillian Phallen; Chul-Kee Park; Christopher M Jackson; Tomas Garzon-Muvdi; Eileen Kim; Debebe Theodros; Magdalena Polanczyk; Allison M Martin; Ian Suk; Xiaobu Ye; Betty Tyler; Chetan Bettegowda; Henry Brem; Drew M Pardoll; Michael Lim
Journal:  Sci Transl Med       Date:  2016-12-21       Impact factor: 17.956

Review 2.  PI3K pathway inhibitors: potential prospects as adjuncts to vaccine immunotherapy for glioblastoma.

Authors:  Taemin Oh; Michael E Ivan; Matthew Z Sun; Michael Safaee; Shayan Fakurnejad; Aaron J Clark; Eli T Sayegh; Orin Bloch; Andrew T Parsa
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

Review 3.  Vaccine therapies in malignant glioma.

Authors:  Taemin Oh; Eli T Sayegh; Shayan Fakurnejad; Daniel Oyon; Jonathan Balquiedra Lamano; Joseph David DiDomenico; Orin Bloch; Andrew T Parsa
Journal:  Curr Neurol Neurosci Rep       Date:  2015-01       Impact factor: 5.081

Review 4.  Tumor Vaccines for Malignant Gliomas.

Authors:  Visish M Srinivasan; Sherise D Ferguson; Sungho Lee; Shiao-Pei Weathers; Brittany C Parker Kerrigan; Amy B Heimberger
Journal:  Neurotherapeutics       Date:  2017-04       Impact factor: 7.620

Review 5.  Developing Therapies for Brain Tumors: The Impact of the Johns Hopkins Hunterian Neurosurgical Research Laboratory.

Authors:  Henry Brem; Eric W Sankey; Ann Liu; Antonella Mangraviti; Betty M Tyler
Journal:  Trans Am Clin Climatol Assoc       Date:  2017

Review 6.  Peptide vaccines for the treatment of glioblastoma.

Authors:  Adam M Swartz; Kristen A Batich; Peter E Fecci; John H Sampson
Journal:  J Neurooncol       Date:  2014-12-10       Impact factor: 4.130

Review 7.  Combination immunotherapy strategies for glioblastoma.

Authors:  Hok Yee Chan; John Choi; Christina Jackson; Michael Lim
Journal:  J Neurooncol       Date:  2021-02-21       Impact factor: 4.130

Review 8.  Evolution of malignant glioma treatment: from chemotherapy to vaccines to viruses.

Authors:  Richard Lee Price; Ennio Antonio Chiocca
Journal:  Neurosurgery       Date:  2014-08       Impact factor: 4.654

Review 9.  Vaccine therapies for patients with glioblastoma.

Authors:  Eli T Sayegh; Taemin Oh; Shayan Fakurnejad; Orin Bloch; Andrew T Parsa
Journal:  J Neurooncol       Date:  2014-08-28       Impact factor: 4.130

Review 10.  Tumor treating fields: a new approach to glioblastoma therapy.

Authors:  Jonathan Rick; Ankush Chandra; Manish K Aghi
Journal:  J Neurooncol       Date:  2018-01-18       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.